Docoh
Loading...

GBT Global Blood Therapeutics

APP
Utility
Substituted Benzaldehyde Compounds and Methods for Their Use In Increasing Tissue Oxygenation
23 Sep 21
Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Brian Metcalf, Chihyuan Chuang, Jeffrey Warrington, Matthew P. Jacobson
Filed: 28 May 21
APP
Utility
Tablets Comprising 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
16 Sep 21
Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets.
Sean Mark Dalziel, Naveen Bejugam, Nazila Habibizad, Ali Komeyli, DeMei Leung
Filed: 20 Jan 21
APP
Utility
Process for Synthesizing 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)-PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
16 Sep 21
Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes.
Zhe Li, Nathan Guz, Yiyang Shao, Julieana Cocuz, Markus Frieser, George Petros Yiannikouros, Liang Liao
Filed: 3 Jun 21
GRANT
Utility
Azaindole compounds as histone methyltransferase inhibitors
7 Sep 21
The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease).
Chul Yu, Ming Yu, Manuel Zancanella, Zhe Li
Filed: 7 Jun 18
APP
Utility
Dosing Regimens for 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
2 Sep 21
Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha, Naveen Bejugam
Filed: 20 May 21
APP
Utility
Compounds and Uses Thereof for the Modulation of Hemoglobin
26 Aug 21
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
Filed: 21 Sep 20
GRANT
Utility
Compounds and uses thereof for the modulation of hemoglobin
6 Jul 21
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Qing Xu, Zhe Li, Stephen L. Gwaltney, II
Filed: 9 Nov 18
APP
Utility
Crystalline Polymorphs of the Free Base of 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
3 Jun 21
Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N.
Zhe Li, Stephan D. Parent, Travis Houston
Filed: 8 Jul 20
GRANT
Utility
Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
1 Jun 21
Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha
Filed: 2 Dec 16
GRANT
Utility
Modulators of hemoglobin
25 May 21
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
Brian W. Metcalf, Zhe Li, Qing Xu, Kobina N. Dufu, James Partridge, Hing Sham, Ming Yu
Filed: 30 Sep 19
APP
Utility
Modulators of Hemoglobin
18 Feb 21
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
Zhe Li
Filed: 4 May 20
GRANT
Utility
Compounds and uses thereof for the modulation of hemoglobin
7 Dec 20
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Qing Xu, Zhe Li
Filed: 11 Apr 19
APP
Utility
Tricyclic Compounds As Histone Methyltransferase Inhibitors
18 Nov 20
Ming YU, Zhe LI, Qing XU, Calvin YEE, Lina SETTI, Hing SHAM
Filed: 12 Aug 18
GRANT
Utility
Histone methyltransferase inhibitors
9 Nov 20
Ming Yu, Zhe Li
Filed: 20 Dec 17
GRANT
Utility
Compounds and uses thereof for the modulation of hemoglobin
9 Nov 20
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
Filed: 29 Mar 18
GRANT
Utility
Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
2 Nov 20
Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Brian Metcalf, Chihyuan Chuang
Filed: 22 Jul 19
GRANT
Utility
Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
19 Oct 20
Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Brian Metcalf, Chihyuan Chuang
Filed: 24 Jun 18
GRANT
Utility
Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
27 Jul 20
Disclosed are crystalline free base an solvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N.
Zhe Li, Stephan D. Parent, Travis Houston
Filed: 17 Oct 18
GRANT
Utility
Methods of treatment
29 Jun 20
This disclosure relates to use of certain aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.
Zhe Li, Jason R. Harris
Filed: 15 May 18
APP
Utility
Ferroportin Inhibitors and Methods of Use
17 Jun 20
The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis.
ZHE LI, Qing Xu, Brian Walter Metcalf, Calvin Wesley Yee, Peter Michael Rademacher, Carsten Alt
Filed: 11 Dec 19
Patents are sorted by USPTO publication date, most recent first